欧盟EMA药品数据库(European Medicines Agency Authorisation of Medicines DataBase)
商品名称Cubicin
适用类别Human
治疗领域Gram-Positive Bacterial Infections;Bacteremia;Soft Tissue Infections;Endocarditis, Bacterial
通用名/非专利名称daptomycin
活性成分daptomycin
产品号EMEA/H/C/000637
患者安全信息No
许可状态Authorised
ATC编码J01XX09
是否额外监管No
是否仿制药或hybrid药物No
是否生物类似药No
是否附条件批准No
是否特殊情形No
是否加速审评No
是否罕用药No
上市许可日期2006/01/19
上市许可开发者/申请人/持有人Merck Sharp & Dohme B.V.
人用药物治疗学分组Antibacterials for systemic use
兽用药物治疗学分组
审评意见日期2005/11/17
欧盟委员会决定日期2025/11/07
修订号41
治疗适应症Cubicin is indicated for the treatment of the following infections. Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI). Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice. Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI. Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
适用物种
兽用药物ATC编码
首次发布日期2018/08/08
最后更新日期2025/11/07
产品说明书https://www.ema.europa.eu/en/documents/product-information/cubicin-epar-product-information_en.pdf
公共评估报告https://www.ema.europa.eu/en/medicines/human/EPAR/cubicin
©2006-2025 DrugFuture->European Medicines Agency Authorisation of Medicines DataBase